QQQ   273.43 (-0.44%)
AAPL   450.77 (-1.06%)
MSFT   214.24 (-0.98%)
FB   273.14 (+2.96%)
GOOGL   1,507.76 (+0.19%)
AMZN   3,206.24 (-0.58%)
NVDA   454.61 (+0.26%)
CGC   17.13 (-2.23%)
BABA   255.26 (-3.92%)
TSLA   1,474.20 (-1.03%)
MU   48.67 (-0.06%)
GE   6.30 (-0.47%)
AMD   85.58 (-1.30%)
T   29.59 (-0.84%)
F   6.82 (-1.59%)
ACB   10.21 (-0.97%)
GILD   68.96 (+0.22%)
NFLX   500.32 (-1.72%)
DIS   130.77 (-0.04%)
BAC   25.40 (-0.27%)
BA   171.01 (-0.69%)
QQQ   273.43 (-0.44%)
AAPL   450.77 (-1.06%)
MSFT   214.24 (-0.98%)
FB   273.14 (+2.96%)
GOOGL   1,507.76 (+0.19%)
AMZN   3,206.24 (-0.58%)
NVDA   454.61 (+0.26%)
CGC   17.13 (-2.23%)
BABA   255.26 (-3.92%)
TSLA   1,474.20 (-1.03%)
MU   48.67 (-0.06%)
GE   6.30 (-0.47%)
AMD   85.58 (-1.30%)
T   29.59 (-0.84%)
F   6.82 (-1.59%)
ACB   10.21 (-0.97%)
GILD   68.96 (+0.22%)
NFLX   500.32 (-1.72%)
DIS   130.77 (-0.04%)
BAC   25.40 (-0.27%)
BA   171.01 (-0.69%)
QQQ   273.43 (-0.44%)
AAPL   450.77 (-1.06%)
MSFT   214.24 (-0.98%)
FB   273.14 (+2.96%)
GOOGL   1,507.76 (+0.19%)
AMZN   3,206.24 (-0.58%)
NVDA   454.61 (+0.26%)
CGC   17.13 (-2.23%)
BABA   255.26 (-3.92%)
TSLA   1,474.20 (-1.03%)
MU   48.67 (-0.06%)
GE   6.30 (-0.47%)
AMD   85.58 (-1.30%)
T   29.59 (-0.84%)
F   6.82 (-1.59%)
ACB   10.21 (-0.97%)
GILD   68.96 (+0.22%)
NFLX   500.32 (-1.72%)
DIS   130.77 (-0.04%)
BAC   25.40 (-0.27%)
BA   171.01 (-0.69%)
QQQ   273.43 (-0.44%)
AAPL   450.77 (-1.06%)
MSFT   214.24 (-0.98%)
FB   273.14 (+2.96%)
GOOGL   1,507.76 (+0.19%)
AMZN   3,206.24 (-0.58%)
NVDA   454.61 (+0.26%)
CGC   17.13 (-2.23%)
BABA   255.26 (-3.92%)
TSLA   1,474.20 (-1.03%)
MU   48.67 (-0.06%)
GE   6.30 (-0.47%)
AMD   85.58 (-1.30%)
T   29.59 (-0.84%)
F   6.82 (-1.59%)
ACB   10.21 (-0.97%)
GILD   68.96 (+0.22%)
NFLX   500.32 (-1.72%)
DIS   130.77 (-0.04%)
BAC   25.40 (-0.27%)
BA   171.01 (-0.69%)
Log in

NASDAQ:CNCEConcert Pharmaceuticals Stock Price, Forecast & News

$10.10
+0.75 (+8.02 %)
(As of 08/7/2020 11:51 AM ET)
Add
Compare
Today's Range
$9.41
Now: $10.10
$10.19
50-Day Range
$8.67
MA: $9.92
$11.52
52-Week Range
$5.36
Now: $10.10
$13.09
Volume2,939 shs
Average Volume114,287 shs
Market Capitalization$299.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Read More
Concert Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.08 million
Book Value$4.26 per share

Profitability

Net Income$-78,170,000.00
Net Margins-97,236.70%

Miscellaneous

Employees71
Market Cap$299.47 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$10.10
+0.75 (+8.02 %)
(As of 08/7/2020 11:51 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

How has Concert Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CNCE shares have increased by 21.0% and is now trading at $10.10.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Concert Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Concert Pharmaceuticals
.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Concert Pharmaceuticals
.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) issued its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.28. Concert Pharmaceuticals had a negative net margin of 97,236.70% and a negative return on equity of 60.38%.
View Concert Pharmaceuticals' earnings history
.

What price target have analysts set for CNCE?

7 equities research analysts have issued 12-month price targets for Concert Pharmaceuticals' shares. Their forecasts range from $10.00 to $30.00. On average, they anticipate Concert Pharmaceuticals' share price to reach $19.50 in the next twelve months. This suggests a possible upside of 93.1% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals
.

Has Concert Pharmaceuticals been receiving favorable news coverage?

Headlines about CNCE stock have trended positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Concert Pharmaceuticals
.

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the following people:
  • Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 61)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 64)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 47)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (4.66%), Russell Investments Group Ltd. (0.58%), Steward Partners Investment Advisory LLC (0.26%), WINTON GROUP Ltd (0.20%), UBS Group AG (0.17%) and Alps Advisors Inc. (0.14%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, Nancy Stuart, Peter Barton Hutt, Richard Aldrich and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals
.

Which institutional investors are selling Concert Pharmaceuticals stock?

CNCE stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Alps Advisors Inc., UBS Group AG, and WINTON GROUP Ltd. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include Nancy Stuart, and Peter Barton Hutt.
View insider buying and selling activity for Concert Pharmaceuticals
.

Which institutional investors are buying Concert Pharmaceuticals stock?

CNCE stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Dupont Capital Management Corp, Russell Investments Group Ltd., SG Americas Securities LLC, Hancock Whitney Corp, and Steward Partners Investment Advisory LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, Richard Aldrich, and Thomas G Auchincloss.
View insider buying and selling activity for Concert Pharmaceuticals
.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $10.10.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $299.47 million and generates $1.08 million in revenue each year. The biotechnology company earns $-78,170,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is www.concertpharma.com.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.